Abstract: An air interface plane (AIP) of a radio frequency (RF) aperture includes: a circuit board having a first side and a second side opposite the first side; and a matrix of tapered elements arranged on the first side of the circuit board and secured to the circuit board, the matrix of tapered elements cooperating to at least one of receive or transmit an over-the-air RF signal. Suitably, each tapered element of the matrix has: a central hub extending along a longitudinal axis from a hub base which is proximate to the first side of the circuit board to an apex of the tapered element which is distal from the first side of the first circuit board; and a plurality of arms extending from the central hub at the apex of the tapered element, each of the plurality of arms including a first portion that projects the arm radially away from the longitudinal axis and a second portion that projects the arm longitudinally toward the first side of the circuit board.

Abstract: The present invention relates to novel therapeutics with antibacterial activity, processes for their preparation, and pharmaceutical, veterinary and nutritional compositions containing them as active ingredients. The present invention also relates to uses of the novel therapeutics, for example, as medicants or food additives in the treatment of bacterial infections or to aid body mass gain in a subject.

Abstract: The present invention relates to novel therapeutics with antibacterial activity, processes for their preparation, and pharmaceutical, veterinary and nutritional compositions containing them as active ingredients. The present invention also relates to uses of the novel therapeutics, for example, as medicants or food additives in the treatment of bacterial infections or to aid body mass gain in a subject.

Abstract: The present invention relates to novel therapeutics with antibacterial activity, processes for their preparation, and pharmaceutical, veterinary and nutritional compositions containing them as active ingredients. The present invention also relates to uses of the novel therapeutics, for example, as medicants or food additives in the treatment of bacterial infections or to aid body mass gain in a subject.

Abstract: The present invention provides a microorganism for the production of 1,3-propanediol from a variety of carbon sources in an organism capable of 1,3-propanediol production and comprising a) at least one gene encoding a dehydratase activity; b) at least one gene encoding a glycerol-3-phosphatase; and c) at least one gene encoding protein X. The protein X may be derived from a Klebsiella or Citrobacter gene cluster. The recombinant microorganism may further comprise d) at least one gene encoding a protein having at least 50% similarity to a protein selected from the group consisting of protein 1 (SEQ ID NO:60 or SEQ ID NO:61), of protein 2 (SEQ ID NO:62 or SEQ ID NO:63) and of protein 3 (SEQ ID NO:64 or SEQ ID NO:65) from Klebsiella or Citrobacter.

Abstract: The present invention provides an improved method for the production of 1,3-propanediol from a variety of carbon sources is an organism comprising DNA encoding protein X of a dehydratase or protein X in combination with at least one of protein 1, protein 2 and protein 3. The protein X may be isolated from a diol dehydratase or a glycerol dehydratase. The present invention also provides host cells comprising protein X that are capable of increased production of 1,3-propanediol.

Abstract: The present invention provides an improved method for the production of 1,3-propanediol from a variety of carbon sources in an organism capable of 1,3-propanediol production and comprising DNA encoding protein X of a microorganismal dehydratase or protein X in combination with at least one of protein 1, protein 2 and protein 3, which proteins are comparable to those encoded by orfY, orfX and orfW, respectively from a microorganismal dha regulon. The protein X may be isolated from a diol dehydratase or a glycerol dehydratase. The present invention also provides host cells comprising protein X that are capable of increased production of 1,3-propanediol.

Abstract: Provided are enzymatic methods for the selective hydrolytic resolution of certain enantiomers of a pharmaceutical compound, the pharmaceutical compound comprising a (.+-.) mixture of a .alpha.-substituted 2-methyl proprionic acid derivative. Specifically provided is the selective enzymatic resolution of either the R(+) or S(-) enantiomer of (.+-.)-ethyl ciprofibrate. Also provided are substantially pure enantiomers of R(+) and S(-) ciprofibrate.